Imagine building a company around a breakthrough cancer therapy, only to discover that the city where you developed it lacks the facilities to manufacture it. This is the reality facing a growing number of Metro Vancouver biotechs, with consequences rippling from the lab bench to the balance sheet.
Metro Vancouver has fewer than 500,000 square feet of purpose-built laboratory space, according to commercial real estate data from CBRE and Colliers International. This is a fraction of the inventory in Seattle or San Diego, which have spent decades cultivating purpose-fitted biotech campuses. Vancouver, despite the research excellence generated at UBC, BC Cancer, and various hospital-based institutes, is attempting to sustain a maturing cluster on infrastructure designed for an earlier era.
The shortage is not merely an inconvenience. Several B.C.-based biotechs—particularly those reaching clinical-stage development and requiring Good Manufacturing Practice (GMP) facilities—are evaluating relocation to U.S. markets. GMP-compliant manufacturing space, which demands rigorous environmental controls, cleanroom certification, and specialized utilities, is effectively unavailable for lease in Metro Vancouver. Companies requiring such space must either fund the construction themselves—a capital commitment that can strain an early-stage balance sheet—or relocate.
The economics of building lab-ready space explain the slow pace of development. Fit-out costs for wet-lab space run between $300 and $600 per square foot, compared with $80 to $120 for standard office space. The infrastructure requirements are demanding: reinforced floor loads, specialized HVAC systems for chemical exhaust, high-capacity electrical service, and precise plumbing configurations. These requirements make retrofitting standard commercial buildings a complex, narrow-margin endeavour.
Yet demand remains robust. Life sciences employment in British Columbia grew approximately 20 per cent between 2020 and 2024, according to LifeSciences BC. The region’s research commercialization pipeline continues to generate spinouts, and the City of Vancouver’s economic strategy has identified life sciences as a priority growth sector, citing its concentration of research talent as a structural advantage.
The relocation threat is practical. When a biotech reaches Series B funding and requires clinical-stage manufacturing, the need for space becomes urgent. Seattle’s South Lake Union neighbourhood offers move-in-ready GMP suites, while San Diego’s Torrey Pines corridor provides incubator campuses with shared equipment. Vancouver lacks an equivalent, leading to a steady pattern of companies raising seed rounds here and Series A rounds elsewhere.
For developers, the opportunity is significant. Life sciences tenants are among the most stable in commercial real estate. Once a firm has installed its equipment and trained its team, relocation is disruptive and costly. Lease terms are typically longer, and anchor tenants—such as hospital systems or research universities—can de-risk a building’s occupancy.
In Metro Vancouver, the most promising development corridors are clustered around existing research infrastructure. UBC's Wesbrook development area is a natural home for lab-ready space, given its proximity to core research facilities. The False Creek Flats also offers zoning flexibility, though translating policy intent into shovel-ready projects has been slow.
Success requires bridge financing and public-private partnerships. In Toronto, the MaRS Discovery District utilized provincial capital and university partnerships to build wet-lab inventory at scale. Vancouver has equivalent anchors in BC Cancer, Vancouver Coastal Health Research Institute, and UBC, but it has yet to connect these institutions to a coherent real estate development strategy.
The bottom line: The sector is succeeding faster than its infrastructure can support. For developers with the appetite for specialized construction, the gap between current supply and the needs of growing biotechs represents a genuine first-mover opportunity.
What to watch: Whether the City of Vancouver's Eastern Core rezoning process accelerates lab-ready permissions in False Creek Flats; any announcements from UBC Properties Trust on Wesbrook commercial development; and federal or provincial capital commitments through InBC Investment Corp.
